Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$111.80

-3.43 (-2.98%)

06:50
06/14/19
06/14
06:50
06/14/19
06:50

Eli Lilly to present findings from SPIRIT-H2H study at EULAR

Eli Lilly announced that the company will present findings from the Phase 3b/4 SPIRIT-Head-to-Head, or H2H, study in patients with active psoriatic arthritis, or PsA, as a late-breaking abstract at the European Congress of Rheumatology, or EULAR. The assessor-blinded, randomized, controlled trial is the first and only H2H study that utilizes on-label dosing for both Taltz and Humira and allows inclusion of concomitant conventional DMARDs. Topline results from the study, which demonstrated Taltz met the primary and all major secondary endpoints, were announced in December 2018. The primary endpoint of the study was superiority for Taltz compared to Humira in the proportion of patients who simultaneously achieved a reduction by at least 50% in disease activity as defined by the American College of Rheumatology, or ACR50, and complete skin clearance as measured by the Psoriasis Area and Severity Index, or PASI 100. Key secondary endpoints included non-inferiority in the proportion of patients who achieved ACR50 and superiority in the proportion of patients who achieved PASI 100. A total of 566 patients with active PsA were enrolled in the SPIRIT-H2H study. Patients were randomized to receive Taltz or Humira at the approved dose for PsA for a total of 52 weeks, with the primary analysis conducted at 24 weeks. PsA patients who also met the study criteria for moderate- to severe plaque psoriasis received Taltz or Humira at the approved dose for psoriasis. At 24 weeks, the proportion of patients achieving both a reduction by at least 50% in disease activity as defined by ACR50 as well as complete skin clearance as measured by PASI 100, was significantly higher for Taltz than for Humira. Taltz also met the key secondary endpoints, including non-inferiority compared to Humira for the percentage of patients achieving ACR50 and superiority compared to Humira for the percentage of patients achieving PASI 100. In SPIRIT-H2H, the safety profile of Taltz was consistent with previously reported results. The most common adverse reactions were mild to moderate in severity, and included infections, injection site reactions, allergic/hypersensitivity reactions and cerebrocardiovascular events. No new safety signals were detected.

  • 30

    Jul

  • 16

    Sep

LLY Eli Lilly
$111.80

-3.43 (-2.98%)

05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
05/28/19
GSCO
05/28/19
INITIATION
Target $135
GSCO
Buy
Eli Lilly initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Eli Lilly with a Buy rating and $135 price target. The company has new product cycles in four large and growing therapeutic categories - diabetes, cancer, pain and immunology, Flynn tells investors in a research note. He believes investors are underappreciating Eli Lilly's longer-term growth potential in diabetes.
06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.61

0.47 (1.09%)

, AMZN

Amazon.com

$1,917.14

7.41 (0.39%)

12:04
06/20/19
06/20
12:04
06/20/19
12:04
Hot Stocks
Comcast to launch Amazon Music on Xfinity services »

Comcast (CMCSA) announced…

CMCSA

Comcast

$43.61

0.47 (1.09%)

AMZN

Amazon.com

$1,917.14

7.41 (0.39%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 10

    Jul

  • 25

    Jul

WORK

Slack Technologies

$0.00

(0.00%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$7.07

-1.04 (-12.82%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
Britannia Bulk falls -13.3% »

Britannia Bulk is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$29.48

-4.73 (-13.83%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -13.9% »

Direxion Daily Junior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$10.11

9.4359 (1,399.78%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
Pier 1 Imports falls -24.6% »

Pier 1 Imports is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$198.00

23.43 (13.42%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 13.7% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$11.06

1.36 (14.02%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 13.9% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TUFN

Tufin

$25.38

3.32 (15.05%)

12:00
06/20/19
06/20
12:00
06/20/19
12:00
Hot Stocks
Tufin rises 14.1% »

Tufin is up 14.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WU

Western Union

$19.80

0.09 (0.46%)

11:55
06/20/19
06/20
11:55
06/20/19
11:55
Options
Western Union put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BJRI

BJ's Restaurants

$43.84

2.53 (6.12%)

11:55
06/20/19
06/20
11:55
06/20/19
11:55
Conference/Events
BJ's Restaurants management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

11:50
06/20/19
06/20
11:50
06/20/19
11:50
General news
Treasury's $75 B in 4- and 8-week bill auctions were well received »

Treasury's $75 B in…

BRKR

Bruker

$48.19

0.45 (0.94%)

11:49
06/20/19
06/20
11:49
06/20/19
11:49
Earnings
Bruker sees medium-term EPS growth of 11%-15%, organic revenue growth of 5%-7% »

Sees FY22 EPS of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Sep

GO

Grocery Outlet

$0.00

(0.00%)

11:46
06/20/19
06/20
11:46
06/20/19
11:46
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BRKR

Bruker

$48.08

0.34 (0.71%)

11:45
06/20/19
06/20
11:45
06/20/19
11:45
Earnings
Bruker sees FY19 EPS $1.57-$1.61, consensus $1.61 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Sep

ZUO

Zuora

$15.64

-0.27 (-1.70%)

11:45
06/20/19
06/20
11:45
06/20/19
11:45
Options
Zuora call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

11:44
06/20/19
06/20
11:44
06/20/19
11:44
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSNL

Personalis

$0.00

(0.00%)

11:42
06/20/19
06/20
11:42
06/20/19
11:42
Syndicate
Breaking Syndicate news story on Personalis »

Personalis opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

UAA

Under Armour

$26.88

-0.08 (-0.30%)

11:40
06/20/19
06/20
11:40
06/20/19
11:40
Conference/Events
Under Armour management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SHOP

Shopify

$330.32

2.92 (0.89%)

11:39
06/20/19
06/20
11:39
06/20/19
11:39
Recommendations
Shopify analyst commentary  »

Shopify price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

HSY

Hershey

$137.38

-0.56 (-0.41%)

, SHOP

Shopify

$328.25

0.85 (0.26%)

11:37
06/20/19
06/20
11:37
06/20/19
11:37
On The Fly
Apple initiation, Shopify downgrade among today's top analyst calls »

Check out today's top…

HSY

Hershey

$137.38

-0.56 (-0.41%)

SHOP

Shopify

$328.25

0.85 (0.26%)

TSLA

Tesla

$220.25

-6.11 (-2.70%)

AMRN

Amarin

$19.69

0.27 (1.39%)

AAPL

Apple

$198.73

0.86 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 28

    Sep

11:36
06/20/19
06/20
11:36
06/20/19
11:36
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:36
06/20/19
06/20
11:36
06/20/19
11:36
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:34
06/20/19
06/20
11:34
06/20/19
11:34
Syndicate
Breaking Syndicate news story on Akero Therapeutics »

Akero Therapeutics opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:32
06/20/19
06/20
11:32
06/20/19
11:32
Syndicate
Breaking Syndicate news story on Akero Therapeutics »

Akero Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

TYPE

Monotype Imaging

$17.90

1.41 (8.55%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Recommendations
Monotype Imaging analyst commentary  »

Private equity buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.